TABLE 5.
Severe maternal morbidity in pregnancy with adenomyosis.
| Adenomyosis (−) | Adenomyosis (+) | aOR (95% CI) a | |
|---|---|---|---|
| Severe maternal morbidity (composite) | |||
| Any b | 2.2 | 6.3 | 1.86 (1.59–2.16)* |
| Except for blood transfusion | 1.1 | 3.4 | 2.00 (1.61–2.48)* |
| Except for blood transfusion/hysterectomy | 0.8 | 2.4 | 2.13 (1.67–2.72)* |
| Individual morbidity indicator c | |||
| Blood products transfusion | 1.5 | 3.9 | 1.73 (1.43–2.09)* |
| Hysterectomy | 0.3 | 1.4 | 2.59 (1.73–3.87)* |
| Coagulopathy | 0.2 | 1.3 | 4.46 (2.97–6.69)* |
| Acute renal failure | 0.3 | 0.5 | 0.95 (0.56–1.54) |
| Sepsis | 0.1 | 0.5 | 4.19 (2.19–8.04)* |
| Shock | 0.1 | 0.5 | 3.59 (1.84–7.03)* |
| Adult respiratory distress syndrome | 0.1 | 0.5 | 2.50 (1.37–4.57)* |
| Other outcome measures | |||
| Postpartum hemorrhage | 4.5 | 8.7 | 1.78 (1.58–2.00)* |
| Total charge ($) | 19 835 | 26 515 | ** |
| Hospital stay ≥7 days | 2.6 | 6.6 | 1.52 (1.29–1.78)* |
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval.
a
Effect size of the exposure group (adenomyosis compared to nonadenomyosis) on outcome measures (severe maternal morbidity). The nonadenomyosis group served as the referent group. The exposure‐outcome association was adjusted for pregnancy factors (placenta previa, placenta accreta spectrum, placenta abruption, and pre‐eclampsia) and delivery factors (gestational age and cesarean delivery).
b
Included any one of the 21 indicators for severe maternal morbidity per the CDC definition.
c
Selected indicators are listed.
*
p < 0.05
**
p < 0.001 (Mann–Whitney U test).